One-Carbon Cofactor Intake and Risk of Neural Tube Defects Among Women Who Meet Folic Acid Recommendations: A Multicenter Case-Control Study. Issue 6 (19th February 2019)

• Record Type: Journal Article
• Authors: Petersen, Julie M; Parker, Samantha E; Crider, Krista S; Tinker, Sarah C; Mitchell, Allen A; Werler, Martha M
• Is Part Of: American journal of epidemiology. Volume 188:Issue 6(2019)
• Page Start: 1136
• Page End: 1143
• Publication Date: 2019-02-19
• Subjects: folic acid -- neural tube defects -- one-carbon group transferases -- primary prevention; Epidemiology -- Periodicals; Public health -- Periodicals; 614.4
• DOI: 10.1093/aje/kwz040
• Languages: English
• ISSNs: 0002-9262

Abstract

Abstract: We aimed to investigate associations between individual and concurrent (≥2) intakes of one-carbon cofactors vitamins B6 and B12, choline, betaine, and methionine and neural tube defect (NTD) outcomes among mothers meeting the folic acid recommendations. In the Slone Birth Defects Study (case-control design; North America, 1998–2015), mothers of 164 NTD cases and 2, 831 nonmalformed controls completed food frequency questionnaires and structured interviews. Estimated intakes of one-carbon cofactors were dichotomized (high vs. low) for all except betaine (low or middle vs. high). We used logistic regression models to estimate odds ratios and 95% confidence intervals adjusted for center, age, and race. The analysis was restricted to mothers with estimated daily total folate intake of ≥400 μg during periconception. Fewer cases, compared with controls, had high intakes for each one-carbon cofactor except betaine, where the starkest contrast occurred in the middle group. Women with concurrent high intakes of B6, B12, choline, and methionine and moderate intake of betaine had approximately half the risk of an NTD-affected pregnancy (odds ratio = 0.49, 95% confidence interval: 0.23, 1.08). These findings suggest that, in the presence of folic acid, one-carbon cofactors—notably when consumed together—might reduce NTD risk. Additional research should inform any changes to clinical recommendations.